GlowDx

GlowDx is a biotechnology startup with a mission to provide Access to diagnosis for all. Founded in 2015 and based in Ireland, the company is focused on developing the World's First True Point-of-Care (POC) Diagnostics Platform to combat Infectious Disease in Emerging Economies. The startup's flagship test targets crucial mosquito-borne infections such as Dengue Fever, Chikungunya & Zika Virus. In addition to this, GlowDx leverages the power of AI and machine learning to model and predict future outbreaks, reinforcing their position at the forefront of healthcare technology and innovation.

The company recently secured a Seed Round investment at 29 July 2022, with the investment coming from SOSV. This support not only provides financial backing but also signifies a vote of confidence from a reputed investor in the startup's vision and potential impact.

GlowDx's efforts not only align with the advancement of biotechnology and healthcare industries but also address a critical global health challenge, particularly in regions with limited access to sophisticated diagnostic tools. The startup's innovative approach and promising technology make it a compelling venture for investors seeking socially impactful and pioneering opportunities in the healthcare sector.